<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="68624"><DrugName>satralizumab</DrugName><DrugNamesKey><Name id="43095152">satralizumab</Name></DrugNamesKey><DrugSynonyms><Name><Value>second generation IL-6 antagonist (mAb, inflammatory disease), Chugai</Value></Name><Name><Value>SA-237</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>sapelizumab</Value></Name><Name><Value>RG-6168</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>satralizumab</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="15414">Chugai Pharmaceutical Co Ltd</CompanyOriginator><CompaniesPrimary><Company id="19446">Roche Holding AG</Company><Company id="15414">Chugai Pharmaceutical Co Ltd</Company></CompaniesPrimary><CrossReferences><SourceEntity id="68624" type="Drug"><TargetEntity id="783240" type="siDrug">Satralizumab</TargetEntity><TargetEntity id="729632" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="15414" type="Company"><TargetEntity id="4295876884" type="organizationId">Chugai Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="19446" type="Company"><TargetEntity id="4295890594" type="organizationId">Roche Holding AG</TargetEntity></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"></TargetEntity><TargetEntity id="D007249" type="MeSH"></TargetEntity><TargetEntity id="-308860612" type="omicsDisease"></TargetEntity><TargetEntity id="1181" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2316" type="ciIndication"><TargetEntity id="G36.0" type="ICD10"></TargetEntity><TargetEntity id="10029322" type="MEDDRA"></TargetEntity><TargetEntity id="D009471" type="MeSH"></TargetEntity><TargetEntity id="71211" type="ORPHANET"></TargetEntity><TargetEntity id="-246318297" type="omicsDisease"></TargetEntity><TargetEntity id="1709" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="471" type="Action"><TargetEntity id="756" type="Mechanism">IL-6 Receptor Antagonists</TargetEntity><TargetEntity id="3056" type="Mechanism">IL-6 Antagonists</TargetEntity><TargetEntity id="1548" type="Mechanism">Anti-IL-6</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00987" type="ciTarget"><TargetEntity id="56621" type="siTarget">IL-6 receptor</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C3">Phase 3 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="2316">Neuromyelitis optica</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="188">Inflammatory disease</Indication><Indication id="291">Rheumatoid arthritis</Indication></IndicationsSecondary><ActionsPrimary><Action id="471">IL-6 receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="589">Sustained release formulation</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="169">Monoclonal antibody humanized</Technology></Technologies><LastModificationDate>2019-05-13T13:09:38.000Z</LastModificationDate><ChangeDateLast>2019-05-15T00:00:00.000Z</ChangeDateLast><AddedDate>2010-10-19T09:48:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="15414" linkType="Company"&gt;Chugai Pharmaceutical&lt;/ulink&gt; and its parent company  &lt;ulink linkID="19446" linkType="Company"&gt;Roche&lt;/ulink&gt;  are developing satralizumab  (SA-237; RG-6168), a long-acting, second-generation humanized IgG2 anti-human IL-6 receptor monoclonal antibody version of  &lt;ulink linkID="6259" linkType="Drug"&gt;tocilizumab&lt;/ulink&gt;, formulated using Chugai's SMART-Ig antibody-recycling technology, for the potential   treatment of neuromyelitis optica (NMO)/NMO spectrum disorder (NMOSD) [&lt;ulink linkID="1519596" linkType="Reference"&gt;1519596&lt;/ulink&gt;], [&lt;ulink linkID="1737896" linkType="Reference"&gt;1737896&lt;/ulink&gt;], [&lt;ulink linkID="2016630" linkType="Reference"&gt;2016630&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2014, a phase III trial in NMO/NMOSD was initiated in Japan [&lt;ulink linkID="1519596" linkType="Reference"&gt;1519596&lt;/ulink&gt;]; in October 2018, the  trial was ongoing  [&lt;ulink linkID="1519596" linkType="Reference"&gt;1519596&lt;/ulink&gt;]. In June 2014, another phase III trial for NMO/NMOSD was  initiated in the US and Europe [&lt;ulink linkID="1531553" linkType="Reference"&gt;1531553&lt;/ulink&gt;]; in December 2018, positive topline data were reported [&lt;ulink linkID="2105393" linkType="Reference"&gt;2105393&lt;/ulink&gt;].  In April 2018, Chugai expected to submit a filing in Japan for NMO in 2019 [&lt;ulink linkID="2027627" linkType="Reference"&gt;2027627&lt;/ulink&gt;]; at that time, Roche also expected submissions  in the US and EU for NMO in 2019 [&lt;ulink linkID="2027862" linkType="Reference"&gt;2027862&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Chugai was previously developing the drug for the potential treatment of rheumatoid arthritis (RA). In December 2010, a phase I trial for RA was initiated in Japan [&lt;ulink linkID="1186966" linkType="Reference"&gt;1186966&lt;/ulink&gt;]. However, in April 2014, the drug was no longer listed on the company's pipeline for that indication  [&lt;ulink linkID="1550360" linkType="Reference"&gt;1550360&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;&lt;ulink linkID="PA5569081" linkType="Patent"&gt;EP-02174667&lt;/ulink&gt; provides protection to July 2028 in Europe, and &lt;ulink linkID="PA6770031" linkType="Patent"&gt;US-08741601&lt;/ulink&gt; and &lt;ulink linkID="PA7151280" linkType="Patent"&gt;JP-05715050&lt;/ulink&gt; provide protection to April 2030 in the US and Japan, respectively.&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In April 2018, a submission in the US for NMO was expected in 2019 [&lt;ulink linkID="2027862" linkType="Reference"&gt;2027862&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2014, the FDA granted the product Orphan designation for NMO and NMOSD [&lt;ulink linkID="1574515" linkType="Reference"&gt;1574515&lt;/ulink&gt;]. In December 2018, the FDA granted Breakthrough Therapy designation for  NMO and NMOSD. The designation was based on the data from the phase III  SAkuraSky trial [&lt;ulink linkID="2105831" linkType="Reference"&gt;2105831&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In April 2018, a submission in the EU for NMO was expected in 2019 [&lt;ulink linkID="2027862" linkType="Reference"&gt;2027862&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2016, the EMA's COMP recommended granting Orphan designation for NMOSD [&lt;ulink linkID="1768270" linkType="Reference"&gt;1768270&lt;/ulink&gt;]; in June 2016, Orphan status was granted [&lt;ulink linkID="1782604" linkType="Reference"&gt;1782604&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In April 2018, Chugai expected to submit a filing for NMO in 2019 [&lt;ulink linkID="2027627" linkType="Reference"&gt;2027627&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In June 2014, a randomized, double blind, multicenter, parallel-assigned, placebo-controlled, phase III trial (&lt;ulink linkID="175441" linkType="Protocol"&gt;NCT02073279&lt;/ulink&gt;; SA-309JG; SAkuraStar) began in the US, Canada, Europe, South Korea, Malaysia, Philippines, Puerto Rico, Singapore and Taiwan in patients (expected total n = 90, expected Taiwan n = 3 to 5) with NMO and NMOSD to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic and immunogenic profiles of satralizumab. The primary endpoint was time to first relapse. In March 2017, the trial was expected to complete  in March 2019  [&lt;ulink linkID="1531553" linkType="Reference"&gt;1531553&lt;/ulink&gt;], [&lt;ulink linkID="1953918" linkType="Reference"&gt;1953918&lt;/ulink&gt;].  In October 2018, enrolment of patients had been completed (n = 95) and primary analysis was pending at the end of the double-blind period  [&lt;ulink linkID="2080520" linkType="Reference"&gt;2080520&lt;/ulink&gt;]. In December 2018, data from 90 patients were reported which showed that the trial met its primary endpoint with a significant reduction in the risk of relapse in patients who received satralizumab compared with placebo [&lt;ulink linkID="2105393" linkType="Reference"&gt;2105393&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2014, a double-blind, randomized, placebo-controlled, parallel-assigned, multicenter, phase III trial (&lt;ulink linkID="166555" linkType="Protocol"&gt;NCT02028884&lt;/ulink&gt;; SA-307JG; 2013-003752-21; SAkuraSky) to evaluate the safety and efficacy of satralizumab in patients (expected total n = 70, expected Taiwan n = 20)  with NMO and NMOSD was  initiated in Japan and Taiwan. The primary endpoint was time to first relapse. In November 2016,  the trial was expected to complete in June 2020. In October 2017,  the trial was initiated in the US, France, Germany, Hungary, Italy, Poland, Spain, Ukarine and the UK [&lt;ulink linkID="1519596" linkType="Reference"&gt;1519596&lt;/ulink&gt;],  [&lt;ulink linkID="1628105" linkType="Reference"&gt;1628105&lt;/ulink&gt;], [&lt;ulink linkID="1953564" linkType="Reference"&gt;1953564&lt;/ulink&gt;]. In June 2018, adult enrollment was completed (n = 76) and the enrollment of adolescents was ongoing [&lt;ulink linkID="2061803" linkType="Reference"&gt;2061803&lt;/ulink&gt;]. In October 2018, data from the trial were presented at the 34th ECTRIMS in Berlin, Germany. At the cut-off date (June 2018), a significant reduction in risk of protocol-defined relapse (62%, p = 0.0184) and relapse (79 and 34% for AQP4+ and AQP4- patients, respectively) was reported. At weeks 48 and 96, the  proportion of patients that were relapse free was 88.9 and 77.6%, respectively, for satralizumab versus 66.0 and 58.7% for placebo. Secondary endpoints were not met as no change in pain or fatigue scores were reported at week 24. Overall, the safety profile was good with similar levels of serious adverse events reported across both groups. Infections were the most  common adverse event reported in both groups (68.3 and 61.9% in treatment and placebo arms, respectively) [&lt;ulink linkID="2080518" linkType="Reference"&gt;2080518&lt;/ulink&gt;], [&lt;ulink linkID="2082539" linkType="Reference"&gt;2082539&lt;/ulink&gt;], [&lt;ulink linkID="2082255" linkType="Reference"&gt;2082255&lt;/ulink&gt;]; in May 2019, further  data were presented at the 71st AAN Annual Meeting in Philadelphia, PA. The majority of AQP4+ patients treated with satralizumab (91.5%) remained relapse free at weeks 48 and 96 (59.9 and 5.38% for placebo, respectively)  [&lt;ulink linkID="2143292" linkType="Reference"&gt;2143292&lt;/ulink&gt;], [&lt;ulink linkID="2150380" linkType="Reference"&gt;2150380&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I studies&lt;/subtitle&gt;In May 2016, clinical data from a first in-human phase I, multiple-dose study which evaluated the pharmacokinetics, pharmacodynamics, safety, and tolerability of satralizumab  in healthy subjects and  in patients with  rheumatoid arthritis were presented at the Second EAN Congress in Copenhagen, Denmark. In single-dose study, healthy subjects received satralizumab (iv 60 or 120 mg or sc 30 to 240 mg) or placebo and patients (n = 33) in multiple-dose study received satralizumab (sc 120 mg q2w in week 0 to 4, then sc 30 to 120 mg q4w) in week 8 to 16. In single-dose study, satralizumab pharmacokinetics were non-linear, and a single-dose of satralizumab sc 120 mg maintained satralizumab concentration inhibiting IL-6 signaling over 1 month. In multiple-dose study, satralizumab concentrations were maintained and C-reactive protein (CRP) levels were remained low with sc 120 mg satralizumab q4w, whereas satralizumab concentrations decreased and CRP increased in other dose groups. Serious adverse events reported were two in multiple-dose study and none in single-dose study [&lt;ulink linkID="1788326" linkType="Reference"&gt;1788326&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2012, data from a phase I study in healthy subjects were presented showing that the recycling antibody satralizumab (120 mg/body; 2.0 mg/kg) persisted in the plasma for about 42 days, compared with a duration of about 17 days for &lt;ulink linkID="6259" linkType="Drug"&gt;tocilizumab&lt;/ulink&gt; (162 mg/body' 2.9 mg/kg)  [&lt;ulink linkID="1356302" linkType="Reference"&gt;1356302&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2010, phase I trials for RA began in Japan [&lt;ulink linkID="1186966" linkType="Reference"&gt;1186966&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In June 2013, preclinical data were presented at the 2013 Annual European Congress of Rheumatology in Madrid, Spain. In collagen-induced arthritis mouse model, treatment with 3mg/kg  prednisolone along with anti-IL-6-receptor antibody improved clinical symptoms significantly when compared with prednisolone alone on day 33. Lumbar vertebral bone mineral density was higher in the mice treated with 3 mg/kg prednisolone plus anti-IL-receptor antibody than in mice treated with 6 mg/kg of prednisolone alone [&lt;ulink linkID="1439288" linkType="Reference"&gt;1439288&lt;/ulink&gt;]. Further data from this  conference demonstrated that   in mice models of collagen-induced arthritis, anti-IL-6R mAb  showed higher anti-arthritic effect with an inhibition ratio of 87% in obese mice than in non-obese mice (62%). In non-arthritic mice, the expression levels of IL-6, TNF-alpha and F4/80 were higher in the hind limbs of obese mice than in non-obese mice [&lt;ulink linkID="1441950" linkType="Reference"&gt;1441950&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2010, preclinical data were published which showed the duration of IL-6 receptor inhibition with the second-generation antibody was 4-fold that  of tocilizumab. The company believed the new technology would also result in a reduction in dose and/or frequency of dosing  [&lt;ulink linkID="1140163" linkType="Reference"&gt;1140163&lt;/ulink&gt;], [&lt;ulink linkID="1140463" linkType="Reference"&gt;1140463&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;The drug is formulated using  Chugai's SMART-Ig technology (Sequential Monoclonal Antibody Recycling Technology Immunoglobulin) that allows a single antibody  to block the function of a target antigen multiple times as the target antigen is released from the antibody within the endosome, allowing the antibody to be recycled back extracellularly and able to bind to another target antigen [&lt;ulink linkID="1140163" linkType="Reference"&gt;1140163&lt;/ulink&gt;], [&lt;ulink linkID="1356302" linkType="Reference"&gt;1356302&lt;/ulink&gt;]. Recycling is achieved by engineering to provide pH-dependent antigen binding; satralizumab binds to the IL-6 receptor at neutral pH and dissociates at acidic pH, resulting in slow plasma clearance, whereas tocilizumab binds to the IL-6 receptor only once and shows rapid plasma clearance [&lt;ulink linkID="1356302" linkType="Reference"&gt;1356302&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, the PDCO  adopted a positive opinion agreeing a pediatric investigation plan (PIP) for the treatment of   neuromyelitis optica   [&lt;ulink linkID="1667442" linkType="Reference"&gt;1667442&lt;/ulink&gt;]. In December 2016, the EMA's Pediatric Committee adopted a positive opinion on modification to the PIP for satralizumab for the treatment of neuromyelitis optica [&lt;ulink linkID="1893809" linkType="Reference"&gt;1893809&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2316">Neuromyelitis optica</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-06-30T00:00:00.000Z</StatusDate><Source id="1531553" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2316">Neuromyelitis optica</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-02-28T00:00:00.000Z</StatusDate><Source id="1519596" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2316">Neuromyelitis optica</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-01T00:00:00.000Z</StatusDate><Source id="1768032" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2316">Neuromyelitis optica</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-02-28T00:00:00.000Z</StatusDate><Source id="1519596" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2316">Neuromyelitis optica</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-01T00:00:00.000Z</StatusDate><Source id="1768032" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2316">Neuromyelitis optica</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-01T00:00:00.000Z</StatusDate><Source id="1768032" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2316">Neuromyelitis optica</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-01T00:00:00.000Z</StatusDate><Source id="1768032" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2316">Neuromyelitis optica</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-01T00:00:00.000Z</StatusDate><Source id="1768032" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-04-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2316">Neuromyelitis optica</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-01T00:00:00.000Z</StatusDate><Source id="1768032" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2316">Neuromyelitis optica</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-01T00:00:00.000Z</StatusDate><Source id="1768032" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2316">Neuromyelitis optica</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-01T00:00:00.000Z</StatusDate><Source id="1768032" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2316">Neuromyelitis optica</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-01T00:00:00.000Z</StatusDate><Source id="1768032" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="XH">Far East</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2316">Neuromyelitis optica</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-01T00:00:00.000Z</StatusDate><Source id="1768032" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-12-31T00:00:00.000Z</StatusDate><Source id="1186966" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2316">Neuromyelitis optica</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-02-28T00:00:00.000Z</StatusDate><Source id="1519596" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2316">Neuromyelitis optica</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-06-30T00:00:00.000Z</StatusDate><Source id="1531553" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2316">Neuromyelitis optica</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-02-28T00:00:00.000Z</StatusDate><Source id="1519596" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="PR">Puerto Rico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2316">Neuromyelitis optica</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-06-30T00:00:00.000Z</StatusDate><Source id="1531553" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2316">Neuromyelitis optica</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-06-30T00:00:00.000Z</StatusDate><Source id="1531553" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-10-18T00:00:00.000Z</StatusDate><Source id="1140163" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><OwnerCompany id="15414">Chugai Pharmaceutical Co Ltd</OwnerCompany><Country id="US">US</Country><Indication id="2316">Neuromyelitis optica</Indication><AwardedIndication>Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-12-19T00:00:00.000Z</MileStoneDate><Source id="2105831" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="15414">Chugai Pharmaceutical Co Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="2316">Neuromyelitis optica</Indication><AwardedIndication>Treatment of neuromyelitis optica spectrum disorders</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-06-27T00:00:00.000Z</MileStoneDate><Source id="1782604" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="15414">Chugai Pharmaceutical Co Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="2316">Neuromyelitis optica</Indication><AwardedIndication>Treatment of neuromyelitis optica spectrum disorders</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-05-19T00:00:00.000Z</MileStoneDate><Source id="1768270" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="15414">Chugai Pharmaceutical Co Ltd</OwnerCompany><Country id="US">US</Country><Indication id="2316">Neuromyelitis optica</Indication><AwardedIndication>Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-06-30T00:00:00.000Z</MileStoneDate><Source id="1574515" type="CORPORATE"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00987"><Name>IL-6 receptor</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>2 references added [&lt;ulink url="utility.reference?i_reference_id=2150380" linkType="reference" linkID="2150380"&gt;2150380&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2143292" linkType="reference" linkID="2143292"&gt;2143292&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="1812420" number="WO-2009014263" title="Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient"></PatentFamily><PatentFamily id="889284" number="WO-2010123014" title="Method for preparing cell highly producing heterogeneous protein"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="14">Tentative</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Roche Holding AG" id="19446"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Osaka University" id="20653"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kyushu University" id="25556"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>